Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01203631 | Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease | PHASE2 | COMPLETED | 78 | — | — | Feb 1, 2011 | May 1, 2013 | Aug 1, 2016 | 23 | United States, Belgium +6 |
| Arm | Type | Description |
|---|---|---|
| NNC 0142-0000-0002 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC 0142-0000-0002 | DRUG | A single dose administered subcutaneously (s.c., under the skin) |
| Placebo | DRUG | A single dose administered subcutaneously (s.c., under the skin) |
Inclusion Criteria: * Subjects with CD for at least 3 months * Subjects not treated before, or subjects who have either not responded to treatment, or responded and then lost the response during continued administration of a therapeutic compound Exclusion Criteria: * Any of the following: Symptom...